Neuroscience and Behavioral Physiology

, Volume 49, Issue 1, pp 60–63 | Cite as

Melatonin – Known and Novel Areas of Clinical Application

  • A. V. ZakharovEmail author
  • E. V. Khivintseva
  • V. F. Pyatin
  • M. S. Sergeeva
  • O. I. Antipov

The mechanisms of action and main clinical effects of melatonin are discussed. The focus is placed on the chronobiological action of melatonin and its adaptogenic and anticancer properties. The commonest manifestations of pineal melatonin deficiency are various functional psychopathological disorders in the form of insomnia, anxiety, or depression. Recommendations for the effective use of melatonin in conditions of melatonin deficiency are given.


Melaxen melatonin chronobiology oncology 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    S. R. Pandi-Perumal, V. Srinivasan, G. J. Maestroni, P. Cardinali, B. Poeggeler, and R. Hardeland, “Melatonin – nature’s most versa- tile biological signal?” FEBS J., 273, No. 13, 2813–2838 (2006), Scholar
  2. 2.
    R. Hardeland, “Melatonin, hormone of darkness and more – occurrence, control mechanisms, actions and bioactive metabolites,” Cell. Mol. Life Sci., 65, No. 13, 2001–2018 (2008), Scholar
  3. 3.
    R. Hardeland, D. P. Cardinali, V. Srinivasan, D. W. Spence, G. M. Brown, and S. R. Pandi-Perumal, “Melatonin – a pleiotropic, orchestrating regulator molecule,” Prog. Neurobiol., 93, No. 3, 350–384 (2011), Scholar
  4. 4.
    A. Carrillo-Vico, J. R. Calvo, P. Abreu, P. J. Lardone, S. Garcia-Maurino, R. J. Reiter, and J. M. Guerrero, “Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance,” FASEB J., 18, No. 3, 537– 539 (2004), Scholar
  5. 5.
    A. Carrillo-Vico, J. M. Guerrero, P. J. Lardone, and R. J. Reiter, “A review of the multiple actions of melatonin on the immune system,” Endocrine, 27, No. 2, 189–200 (2005), 27:2:189.Google Scholar
  6. 6.
    G. Huether, “The contribution of extrapineal sites of melatonin synthesis to circulating melatonin levels in higher vertebrates,” Experientia, 49, No. 8, 665–670 (1993), Scholar
  7. 7.
    D. X. Tan, L. C. Manchester, R. Hardeland, et al., “Melatonin – a hormone, a tissue factor, an autaocoid, a paracoid, and an antioxidant vitamin,” J. Pin. Res., 34, No. 1, 75–78 (2003), 1034/j.1600-079x.2003.02111.x.Google Scholar
  8. 8.
    R. J. Reiter, D. X. Tan, J. C. Mayo, R. M. Sainz, J. Leon, and Z. Czarnocki, “Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans,” Acta Biochim. Pol., 50, No. 4, 1129–1146 (2003).PubMedGoogle Scholar
  9. 9.
    A. López, J. A. García, G. Escames, et al., “Melatonin protects the mitochondria from oxidative damage reducing oxygen consumption, membrane potential, and superoxide anion production,” J. Pin. Res., 46, No. 2, 188–198 (2009), Scholar
  10. 10.
    I. E. Marks, Cure and Care of Neurosis, Scott Medical Foundation, New York (2001).Google Scholar
  11. 11.
    C. I. Campos, C. H. Nogueira, and L. Fernandes, “Aging, circadian rhythms and depressive disorders: A review,” Am. J. Neurodegener. Dis., 2, 228–246 (2013).Google Scholar
  12. 12.
    E. Katagiri, “Studies on the pineal gland; tumor proliferation and the pineal gland,” Osaka Igakkai Zasshi, 43, 315–320 (1944).Google Scholar
  13. 13.
    M. Nakatani, Y. Ohara, E. Katagiri, and K. Nakano, “Studien uber die Zirbellosen weiblichen weissen Ratten,” Nippon Byori Gakkai Kaishi, 30, 232–236 (1940).Google Scholar
  14. 14.
    J. Drexler, T. F. Meaney, and L. J. McCormack, “The calcified pineal body and carcinoma,” Cleve. Clin. Q., 24, 242–247 (1957), Scholar
  15. 15.
    K. W. Starr, “Hormonal imbalance and the sarcomata,” Aust. NZ J. Surg., 39, 142–150 (1969), tb05577.Google Scholar
  16. 16.
    G. A. Smythe and L. Lazarus, “Growth hormone regulation by melatonin and serotonin,” Nature, 244, 230–231 (1973), Scholar
  17. 17.
    J. K. Burns, “Administration of melatonin to non-human primates and to women with breast carcinoma,” J. Physiol., 229, 38–39 (1973).Google Scholar
  18. 18.
    E. Tapp and M. Blumfield, “The weight of the pineal gland in malignancy,” Br. J. Cancer, 24, 67–70 (1970), Scholar
  19. 19.
    L. Di Bella, M. T. Rossi, and G. Scalera, “Perspectives in pineal functions,” Prog. Brain Res., 52, 475–478 (1979), Scholar
  20. 20.
    V. Srinivasan, S. R. Pandi-Perumal, A. Brzezinski, K. P. Bhatnagar, and D. P. Cardinali, “Melatonin, immune function and cancer,” Recent Pat. Endocr. Metab. Immune Drug Discov., 5, 109–123 (2011), Scholar
  21. 21.
    M. Sanchez-Hidalgo, M. Lee, C. A. de la Lastra, J. M. Guerrero, and G. Packham, “Melatonin inhibits cell proliferation and induces caspase activation and apoptosis in human malignant lymphoid cell lines,” J. Pineal Res., 53, 366–373 (2012), Scholar
  22. 22.
    Q. Zhou, S. Gui, and Y. Wang, “Melatonin inhibits the migration of human lung adenocarcinoma A549 cell lines involving JNK/MAPK pathway,” PLoS One, 9, 101–132 (2014), Scholar
  23. 23.
    S. Y. Park, W. J. Jang, E. Y. Yi, J. Y. Jang, Y. Jung, J. W. Jeong, and Y. J. Kim, “Melatonin suppresses tumor angiogenesis by inhibiting HIF-1alpha stabilization under hypoxia,” J. Pineal Res., 48, 178–184 (2010), Scholar
  24. 24.
    E. Mills, P. Wu, D. Seely, and G. Guyatt, “Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis,” J. Pineal Res., 39, 360–366 (2005 Scholar
  25. 25.
    D. Seely, P. Wu, H. Fritz, D. A. Kennedy, T. Tsui, A. J. Seely, and E. Mills, “Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials,” Integr. Cancer Ther., 21, 21 (2011), Scholar
  26. 26.
    Y. M. Wang, B. Z. Jin, F. Ai, C. H. Duan, Y. Z. Lu, T. F. Dong, and Q. Fu, “The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials,” Cancer Chemother. Pharmacol., 69, 1213–1220 (2012), Scholar
  27. 27.
    A. Sookprasert, N. P. Johns, A. Phunmanee, et al., “Melatonin in patients with cancer receiving chemotherapy: A randomized, doubleblind, placebo-controlled trial,” Anticancer Res., 34, No. 12, 7327–7337 (2014).PubMedGoogle Scholar
  28. 28.
    M. A. Ben-David, R. Elkayam, I. Gelernter, and R. M. Pfeffer, “Melatonin for prevention of breast radiation dermatitis: A phase II, prospective, double-blind randomized trial,” Isr. Med. Assoc. J., 18, No. 3–4, 188–192 (2016).PubMedGoogle Scholar
  29. 29.
    C. Rodriguez, V. Martin, F. Herrera, et al., “Mechanisms involved in the pro-apoptotic effect of melatonin in cancer cells,” Int. J. Mol. Sci., 14, 6597–6613 (2013), 14046597.Google Scholar
  30. 30.
    E. B. Arushanyan and E. V. Beier, “The pineal hormone melatonin – a universal natural adaptogen,” Usp. Fiziol. Nauk., 43, No. 3, 82–100 (2012), Scholar
  31. 31.
    M. G. Poluektov, E. A. Aristakesyan, R. V. Buzunov, et al., Somnology and Sleep Medicine. National Guidelines in Memory of A. M. Vein and Ya. I. Levin, M. G. Poluektov (ed.) Medforum, Moscow (2016).Google Scholar
  32. 32.
    E. B. Arushanyan, “Universal therapeutic potential of melatonin,” Klin. Med., 91, No. 2, 4–8 (2013).Google Scholar
  33. 33.
    E. B. Arushanyan, “Melatonin and diabetes mellitus (review of contemporary experimental data),” Prob. Endokrinol., 58, No. 3, 35–40 (2012),
  34. 34.
    V. I. Konenkov, V. V. Klimontov, S. V. Michurina, M. A. Prudnikova, and I. Yu. Ishchenko, “Melatonin in diabetes mellitus: from pathophysiology to treatment perspectives,” Sakhar. Diabet, 59, 11–16 (2013),
  35. 35.
    K. V. Danilenko, “Melatonin, blood lipid profiles, and atherosclerosis: review of clinical studies,” Ateroskleroz, 8, No. 1, 36–42 (2012).Google Scholar
  36. 36.
    M. G. Poluektov, Ya. I. Levin, A. N. Boiko, et al., “Results of a Russian multicenter trial of the efficacy and safety of Melaxen (melatonin) for the treatment of sleep disorders in patients with chronic cerebrovascular failure,” Zh. Nevrol. Psikhiat., 112, No. 9, 26–31 (2012).Google Scholar
  37. 37.
    N. V. Fedorova, A. V. Nikitina, and E. V. Gubanova, “The role of melatonin in the treatment of primary sleep impairments in patients with Parkinson’s disease,” Consilium Medicum, Nevrol./Revmatol., 2, 84–90 (2012).Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • A. V. Zakharov
    • 1
    Email author
  • E. V. Khivintseva
    • 1
  • V. F. Pyatin
    • 1
  • M. S. Sergeeva
    • 1
  • O. I. Antipov
    • 2
  1. 1.Samara State Medical UniversitySamaraRussia
  2. 2.Volga State University of Telecommunications and InformaticsSamaraRussia

Personalised recommendations